JNJ - Is Emergent BioSolutions Still a Buy After Its Coronavirus Vaccine Flub?
Bad news can be good news if you're an investor with a long time horizon and guts of steel. Every time a stock takes a body blow from an ugly reveal, there's an opportunity to buy at a discount.
That's the logic that might lead someone to consider picking up a few shares of Emergent BioSolutions (NYSE: EBS) right now. In the course of its work as a contract manufacturer for Johnson & Johnson (NYSE: JNJ) , failures at an Emergent facility led to millions of contaminated coronavirus vaccine doses being discarded during a time of desperate need.
Now, the company's competence is in question, and the negative headlines just won't stop coming. Are Emergent's troubles a buying opportunity of a lifetime, or should investors stay far away from the stock?
For further details see:
Is Emergent BioSolutions Still a Buy After Its Coronavirus Vaccine Flub?